Total Payments
$391,606
2024 Payments
$54,898
Companies
17
Transactions
320
Medicare Patients
1,861
Medicare Billing
$217,702
Payment Breakdown by Category
Other$319,223 (81.5%)
Travel$49,626 (12.7%)
Consulting$13,240 (3.4%)
Food & Beverage$9,428 (2.4%)
Education$88.99 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $319,195 | 105 | 81.5% |
| Travel and Lodging | $49,626 | 98 | 12.7% |
| Consulting Fee | $13,240 | 18 | 3.4% |
| Food and Beverage | $9,428 | 91 | 2.4% |
| Education | $88.99 | 7 | 0.0% |
| Honoraria | $28.75 | 1 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $153,452 | 111 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $105,505 | 86 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $25,875 | 18 | $0 (2024) |
| GENZYME CORPORATION | $23,789 | 15 | $0 (2021) |
| Novartis Pharmaceuticals Corporation | $15,232 | 20 | $0 (2019) |
| Genentech USA, Inc. | $15,004 | 13 | $0 (2017) |
| Daiichi Sankyo Inc. | $14,668 | 14 | $0 (2023) |
| EISAI INC. | $12,686 | 11 | $0 (2019) |
| Stemline Therapeutics Inc. | $11,345 | 8 | $0 (2024) |
| Array BioPharma Inc. | $10,409 | 13 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $54,898 | 38 | AstraZeneca Pharmaceuticals LP ($27,405) |
| 2023 | $55,704 | 43 | AstraZeneca Pharmaceuticals LP ($22,524) |
| 2022 | $61,811 | 51 | AstraZeneca Pharmaceuticals LP ($29,365) |
| 2021 | $37,396 | 27 | AstraZeneca Pharmaceuticals LP ($15,967) |
| 2020 | $10,350 | 9 | E.R. Squibb & Sons, L.L.C. ($7,314) |
| 2019 | $72,512 | 61 | E.R. Squibb & Sons, L.L.C. ($26,192) |
| 2018 | $40,616 | 33 | AstraZeneca Pharmaceuticals LP ($27,266) |
| 2017 | $58,319 | 58 | AstraZeneca Pharmaceuticals LP ($18,325) |
All Payment Transactions
320 individual payment records from CMS Open Payments — Page 1 of 13
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/10/2024 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,200.00 | General |
| Category: Oncology | ||||||
| 11/04/2024 | AstraZeneca Pharmaceuticals LP | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,360.00 | General |
| 10/23/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,340.00 | General |
| Category: Oncology | ||||||
| 10/16/2024 | AstraZeneca Pharmaceuticals LP | — | Travel and Lodging | In-kind items and services | $877.63 | General |
| 10/16/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $125.00 | General |
| 10/04/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,854.00 | General |
| Category: Oncology | ||||||
| 10/02/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Travel and Lodging | Cash or cash equivalent | $29.61 | General |
| Category: Oncology | ||||||
| 09/18/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $121.89 | General |
| Category: Oncology | ||||||
| 09/05/2024 | Stemline Therapeutics Inc. | Orserdu (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,860.00 | General |
| Category: Oncology | ||||||
| 08/27/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,450.00 | General |
| Category: Oncology | ||||||
| 08/21/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Travel and Lodging | In-kind items and services | $992.52 | General |
| Category: Oncology | ||||||
| 08/21/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $87.36 | General |
| Category: Oncology | ||||||
| 08/13/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,350.00 | General |
| Category: Oncology | ||||||
| 07/23/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Travel and Lodging | In-kind items and services | $903.89 | General |
| Category: ONCOLOGY | ||||||
| 07/22/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,704.00 | General |
| Category: ONCOLOGY | ||||||
| 07/18/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $112.09 | General |
| Category: ONCOLOGY | ||||||
| 07/10/2024 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Food and Beverage | In-kind items and services | $113.39 | General |
| Category: Oncology | ||||||
| 07/10/2024 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Travel and Lodging | In-kind items and services | $29.61 | General |
| Category: Oncology | ||||||
| 05/29/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Travel and Lodging | In-kind items and services | $618.67 | General |
| Category: Oncology | ||||||
| 05/29/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $48.70 | General |
| Category: Oncology | ||||||
| 05/15/2024 | Stemline Therapeutics Inc. | Orserdu (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,100.00 | General |
| Category: Oncology | ||||||
| 05/15/2024 | Stemline Therapeutics Inc. | Orserdu (Drug) | Travel and Lodging | In-kind items and services | $854.20 | General |
| Category: Oncology | ||||||
| 05/15/2024 | Stemline Therapeutics Inc. | Orserdu (Drug) | Food and Beverage | In-kind items and services | $110.53 | General |
| Category: Oncology | ||||||
| 05/09/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Travel and Lodging | In-kind items and services | $30.95 | General |
| Category: ONCOLOGY | ||||||
| 04/30/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,704.00 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 476 | 791 | $332,447 | $53,811 |
| 2022 | 8 | 477 | 887 | $374,147 | $62,711 |
| 2021 | 8 | 507 | 811 | $327,308 | $61,453 |
| 2020 | 7 | 401 | 728 | $218,961 | $39,727 |
Total Patients
1,861
Total Services
3,217
Medicare Billing
$217,702
Procedure Codes
31
All Medicare Procedures & Services
31 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 230 | 455 | $161,070 | $23,198 | 14.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 92 | 147 | $73,794 | $11,641 | 15.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 67 | 67 | $57,084 | $9,330 | 16.3% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 13 | 27 | $10,557 | $2,674 | 25.3% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Facility | 2023 | 28 | 37 | $4,033 | $1,816 | 45.0% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 15 | 16 | $7,884 | $1,729 | 21.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 16 | 16 | $11,184 | $1,712 | 15.3% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 15 | 26 | $6,841 | $1,712 | 25.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 190 | 377 | $129,905 | $19,006 | 14.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 138 | 253 | $122,254 | $18,523 | 15.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 68 | 68 | $55,886 | $10,017 | 17.9% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 19 | 112 | $41,664 | $9,557 | 22.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 17 | 18 | $12,072 | $1,974 | 16.4% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 14 | 22 | $5,054 | $1,290 | 25.5% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Facility | 2022 | 19 | 24 | $2,562 | $1,281 | 50.0% |
| 99221 | Initial hospital inpatient care per day, typically 30 minutes | Facility | 2022 | 12 | 13 | $4,750 | $1,064 | 22.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 154 | 270 | $115,785 | $20,983 | 18.1% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 163 | 261 | $79,520 | $12,696 | 16.0% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 69 | 69 | $53,799 | $10,134 | 18.8% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 55 | 73 | $41,420 | $8,367 | 20.2% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 24 | 74 | $24,288 | $6,359 | 26.2% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 14 | 30 | $6,810 | $1,793 | 26.3% |
| 99212 | Established patient outpatient visit, total time 10-19 minutes | Facility | 2021 | 17 | 22 | $4,558 | $663.96 | 14.6% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Facility | 2021 | 11 | 12 | $1,128 | $457.22 | 40.5% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 188 | 362 | $87,617 | $13,649 | 15.6% |
About Dr. Scott Christensen, M.D
Dr. Scott Christensen, M.D is a Hematology & Oncology healthcare provider based in Sacramento, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/16/2005. The National Provider Identifier (NPI) number assigned to this provider is 1316923899.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Scott Christensen, M.D has received a total of $391,606 in payments from pharmaceutical and medical device companies, with $54,898 received in 2024. These payments were reported across 320 transactions from 17 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($319,195).
As a Medicare-enrolled provider, Christensen has provided services to 1,861 Medicare beneficiaries, totaling 3,217 services with total Medicare billing of $217,702. Data is available for 4 years (2020–2023), covering 31 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Sacramento, CA
- Active Since 12/16/2005
- Last Updated 08/29/2019
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1316923899
Products in Payments
- OPDIVO (Biological) $100,455
- LYNPARZA (Drug) $59,621
- LIBTAYO (Biological) $38,919
- FASLODEX (Drug) $36,911
- ENHERTU (Biological) $34,590
- KISQALI (Drug) $15,232
- Zelboraf (Biological) $15,004
- Halaven (Drug) $12,686
- Orserdu (Drug) $11,345
- LIBTAYO (Drug) $10,745
- Braftovi (Drug) $10,409
- ENHERTU (Drug) $7,413
- Enhertu (Drug) $6,423
- Turalio (Drug) $832.50
- IMLYGIC (Biological) $700.00
- Cabometyx (Drug) $75.00
- Rubraca (Drug) $60.00
- IBRANCE (Drug) $57.40
- Nerlynx (Drug) $26.09
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Sacramento
Dr. Joseph Tuscano, M.d, M.D
Hematology & Oncology — Payments: $633,262
Hematology & Oncology $633,262
Adam Giermasz, M.d., Phd, M.D., PHD
Hematology & Oncology — Payments: $518,605
Hematology & Oncology $518,605
Dr. David Gandara, M.d, M.D
Hematology & Oncology — Payments: $462,968
Hematology & Oncology $462,968
Karen Kelly, M.d, M.D
Hematology & Oncology — Payments: $306,992
Hematology & Oncology $306,992
Paul Kaesberg, M.d, M.D
Hematology & Oncology — Payments: $221,939
Hematology & Oncology $221,939
Dr. Edward Kim, M.d., Phd, M.D., PHD
Hematology & Oncology — Payments: $145,977
Hematology & Oncology $145,977